EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study

Alfredo García-Layana, Gloria C Chi, Laurent Kodjikian, Mariacristina Parravano, David Chow, Timothy L Jackson, Carl Danzig, Liliana P Paris, Mirela Mirt, Mickael Henry-Szatkowski, Hannah B Lewis, Brittany Gentile

Ophthalmic Research · 2024

DOI: 10.1159/000541349 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Ophthalmic Research, 2024. Verfasst von Alfredo García-Layana und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Diabetic Retinopathy, Macular Edema, Patient Preference. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

New anti-vascular endothelial growth factor (VEGF) treatments are emerging for the treatment of diabetic macular edema (DME)/neovascular age-related macular degeneration (nAMD). This study aimed to explore the treatment attributes patients find important when deciding on treatment options.

Methods

This noninterventional survey study assessed treatment preferences through a discrete choice experiment (DCE) among patients with DME/nAMD in the USA, Canada, France, Italy, Spain, and the UK. The DCE design was informed by a targeted literature review and qualitative interview research and included five treatment attributes: mode of administration, frequency of examinations, frequency of injections or refills, likely change in visual acuity, and eye-related side effects. Conditional logit models were used to analyze the choice data.

Results

Overall, 537 patients completed the DCE (DME, n = 173; nAMD, n = 364). Patients reported preferring “injection” over “implant surgery and refills” and better visual outcomes over “stabilization,” which were also the most important attributes driving preference (35.1% and 31.5%, respectively). They also showed a preference for less-frequent treatment and examinations and for “mild-moderate, frequent” over “severe, rare” side effects. These findings were generally consistent across the two conditions, although significant differences were found depending on anti-VEGF treatment duration (nAMD, DME) and number of reported barriers (nAMD).

Conclusion

Patient preferences for treatment are driven by several factors. Considering these preferences is essential when designing/introducing new therapies. Individual treatment preferences should be identified and given key consideration when helping patients select from an expanding array of treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsDiabetic RetinopathyMacular EdemaPatient PreferenceVascular Endothelial Growth Factor AVisual AcuityWet Macular DegenerationAgedAged, 80 and overFemaleHumansMaleMiddle AgedIntravitreal InjectionsRanibizumabSurveys and Questionnaires

Stichwörter der Autor:innen

Anti-vascular endothelial growth factor treatmentDiabetic macular edemaDiscrete choice experimentNeovascular age-related macular degenerationPatient preference

Substanzen

Angiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
  • Genentech, Inc., South San Francisco, California, USA.
  • Department of Ophthalmology, Hôpital Universitaire de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
  • UMR-CNRS 5510 Matéis, Insa, University of Lyon, Lyon, France.
  • IRCCS-Fondazione Bietti, Rome, Italy.
  • Toronto Retina Institute, Toronto, Ontario, Canada.

Zitieren

APA

García-Layana, A., Chi, G. C., Kodjikian, L., Parravano, M., Chow, D., Jackson, T. L., Danzig, C., Paris, L. P., Mirt, M., Henry-Szatkowski, M., Lewis, H. B., & Gentile, B. (2024). Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study. Ophthalmic Research. https://doi.org/10.1159/000541349

Vancouver

García-Layana A, Chi GC, Kodjikian L, Parravano M, Chow D, Jackson TL, et al. Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study. Ophthalmic Research. 2024. doi:10.1159/000541349

BibTeX
@article{GarcaLayana2024,
  author = {García-Layana, Alfredo and Chi, Gloria C and Kodjikian, Laurent and Parravano, Mariacristina and Chow, David and Jackson, Timothy L and Danzig, Carl and Paris, Liliana P and Mirt, Mirela and Henry-Szatkowski, Mickael and Lewis, Hannah B and Gentile, Brittany},
  title = {Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study},
  journal = {Ophthalmic Research},
  year = {2024},
  doi = {10.1159/000541349}
}
Kostenlos starten →